New Life Health Products Ginkgo Biloba 2500

Maa: Australia

Kieli: englanti

Lähde: Department of Health (Therapeutic Goods Administration)

Aktiivinen ainesosa:

Ginkgo biloba, Quantity: 50 mg (Equivalent: Ginkgo biloba, Qty 2.5 g; Equivalent: Ginkgolides and bilobalide, Qty 3 mg; Equivalent: Ginkgo flavonglycosides, Qty 12 mg)

Saatavilla:

Evergrowth Pty Ltd

Lääkemuoto:

Tablet, film coated

Koostumus:

Excipient Ingredients: hypromellose; colloidal anhydrous silica; povidone; macrogol 400; calcium hydrogen phosphate dihydrate; magnesium stearate; microcrystalline cellulose; crospovidone; Carnauba Wax

Antoreitti:

Oral

luokka:

Medicine Listed

Käyttöaiheet:

Antioxidant/Reduce free radicals formed in the body ; Maintain/support healthy hearing ; Maintain/support general health and wellbeing ; Maintain/support healthy blood circulation ; Maintain/support blood circulation/flow to the peripheral areas of the body (legs, hands and feet) ; Maintain/support blood capillary health ; Decrease/reduce/relieve aching/tired legs/leg heaviness associated with mild varicose veins ; Maintain/support mental concentration/focus/clarity ; Enhance/improve/promote/increase mental alertness/wakefulness ; Maintain/support memory/mental recall

Tuoteyhteenveto:

Visual Identification: ; Container Type: Bottle

Valtuutuksen tilan:

Licence status A

Valtuutus päivämäärä:

1999-11-04

Pakkausseloste

TERTROXIN- Consumer Medicine Information
Page 1 of 3
TERTROXIN
_liothyronine sodium _
CONSUMER MEDICINE INFORMATION (CMI)
WHAT IS IN THIS LEAFLET
This leaflet answers some common
questions about TERTROXIN. It
does not contain all the available
information.
It does not take the place of talking
to your doctor or pharmacist.
All medicines have risks and
benefits. Your doctor has weighed
the risks of you taking
TERTROXIN against the benefits
he/she expects it will have for you.
ASK YOUR DOCTOR OR PHARMACIST IF
YOU HAVE ANY CONCERNS ABOUT
TAKING THIS MEDICINE,
KEEP THIS LEAFLET WITH THE
MEDICINE.
You may need to read it again.
WHAT TERTROXIN IS USED
FOR
TERTROXIN contains
“liothyronine” which is a naturally
occurring thyroid hormone.
It is used for treating:
•
disorders of thyroid deficiency
or low thyroid levels in the
body
•
coma or unconsciousness
caused by severely low thyroid
levels in the body
•
an overactive thyroid gland
which occurs in thyrotoxicosis
or Grave’s Disease, together
with other medicines
•
a low thyroid level after
treatment of thyrotoxicosis.
ASK YOUR DOCTOR IF YOU HAVE ANY
QUESTIONS ABOUT WHY
TERTROXIN HAS BEEN
PRESCRIBED FOR YOU.
Your doctor may have prescribed
TERTROXIN for another reason.
This medicine is only available
with a doctor’s prescription.
There is no evidence that
TERTROXIN is addictive.
BEFORE YOU USE IT
_WHEN YOU MUST NOT TAKE IT_
_ _
_ _
DO NOT TAKE TERTROXIN IF:
•
YOU HAVE AN ALLERGY TO
TERTROXIN OR ANY OF THE
INGREDIENTS LISTED AT THE END
OF THIS LEAFLET
•
YOU HAVE ANGINA
•
YOU HAVE ANY OTHER HEART
CONDITION
•
YOU HAVE AN UNTREATED
ADRENAL GLAND CONDITION
DO NOT TAKE TERTROXIN IF THE
PACKAGING IS TORN OR SHOWS SIGNS
OF TAMPERING. DO NOT TAKE
TERTROXIN IF THE EXPIRY DATE
(EXP) PRINTED ON THE PACK HAS
PASSED.
If you take this medicine after the
expiry date has passed, it may not
work.
IF YOU ARE NOT SURE WHETHER YOU
SHOULD START TAKING
TERTROXIN, CONTACT YOUR
DOCTOR.
_BEFORE YOU START TO TAKE IT_
TELL YOUR DOCTOR IF YOU HAVE
ALLERGIES TO ANY OTHER FOODS,

Valmisteyhteenveto

1
AUSTRALIAN PRODUCT INFORMATION
TERTROXIN (LIOTHYRONINE SODIUM) TABLET
1
NAME OF THE MEDICINE
Liothyroinine sodium
2
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each tablet contains 20 microgram liothyronine sodium. The excipients
include sodium
chloride and lactose. For the full list of excipients, see Section 6.1
List of excipients.
3
PHARMACEUTICAL FORM
Tablet - white, uncoated, plain on one side and with a break line on
the other.
4
CLINICAL PARTICULARS
4.1
T
HERAPEUTIC INDICATIONS
Tertroxin is indicated in the treatment of: coma due to myxoedema;
management of severe
thyroid deficiency; hypothyroid states arising in treatment of
thyrotoxicosis.
Tertroxin may be preferred for treating severe and acute hypothyroid
states because of its
rapid and more potent effect but thyroxine sodium is normally the drug
of choice for routine
replacement therapy.
Tertroxin can also be used therapeutically in the treatment of
thyrotoxicosis as an adjunct to
carbimazole in order to prevent sub-clinical hypothyroidism developing
during treatment.
4.2
D
OSE AND METHOD OF ADMINISTRATION
In myxoedema unless an immediate effect is needed, it is best to begin
with small doses, 10-
20 microgram every 8 hours, increasing by steps, if necessary, to a
total daily dosage of 60
microgram administered in divided doses. This dosage usually suffices
for maintenance, but
for continuous maintenance it is generally considered that thyroxine
is desirable, for its
disadvantages in treating manifestations of hypometabolism are
advantages where therapy
has to be continuous throughout life.
Treatment of myxoedema coma should be initiated under specialist
supervision. Sixty
microgram may be given by stomach tube, then 20 microgram every 8
hours, although it is
more usual to start treatment with intravenous liothyronine.
As therapy for thyrotoxicosis with carbimazole: In adults 20 microgram
of liothyronine every
8 hours.
For children and elderly patients it is suggested that the initial
dosage should be 5 microgram
daily. In children the daily dosage of